CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting
May 17 2017 - 8:00AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced an upcoming poster
presentation for its lead product candidate, CX-072, a PD-L1
targeting Probody therapeutic for the treatment of cancer, at the
American Society of Clinical Oncology Annual Meeting from June 2-6,
2017 in Chicago, Illinois.
“The occurrence of immune-related adverse events is emerging as
the Achilles’ heel of cancer immunotherapy,” said Rachel W.
Humphrey, M.D., chief medical officer of CytomX Therapeutics.
“Our recently initiated Phase 1/2 clinical trial, part of our
umbrella PROCLAIM program, is investigating the potential of our
differentiated, anti-PD-L1 Probody therapeutic, CX-072, to reduce
overactivation of the immune system outside of the tumor, while
remaining active as a single-agent and in combination therapy.
This poster presentation at ASCO will review the design and
objectives of this ongoing study.”
Abstract Information
Title: |
PROCLAIM-001: A first-in-human trial to assess tolerability of the
protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and
lymphomas |
Author: |
Alexander I. Spira, M.D., Ph.D., F.A.C.P., Medical Oncologist and
Director, Virginia Cancer Specialists Research Institute and
Oncology Research |
Session: |
Developmental Therapeutics—Immunotherapy |
Date: |
Monday,
June 5, 2017 |
Time: |
8:00
a.m. - 11:30 a.m. |
Location: |
Hall
A |
Abstract: |
TPS3107 |
About the PROCLAIM-CX-072 Trial PROCLAIM-CX-072
is the first clinical trial under the international umbrella
program, PROCLAIM. The trial is an open-label, dose-finding Phase
1/2 study evaluating CX-072 as monotherapy and in combination with
Yervoy® (ipilimumab) or Zelboraf®(vemurafenib). As part of the
study, CytomX aims to achieve three goals as part of the
PROCLAIM-072 clinical trial:
- Tolerability: Demonstrate that CX-072 is well tolerated in
patients and potentially improves safety, particularly in the
combination setting.
- Anti-cancer activity: Demonstrate initial evidence of CX-072’s
anti-cancer activity as monotherapy and in combination.
- Translational program and Probody platform proof-of-concept:
Explore mechanistic aspects of Probody activity in patients as
observed in preclinical studies.
More information about the trial is available at
clinicaltrials.gov.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. The Company uses its
platform to create proprietary cancer immunotherapies against
clinically-validated targets, such as PD-L1, and develop
first-in-class cancer therapeutics against difficult-to-drug
targets, such as CD166. Probody therapeutics are designed to take
advantage of unique conditions in the tumor microenvironment to
enhance the tumor-targeting features of an antibody and reduce drug
activity in healthy tissues. The Company’s lead program, CX-072, a
wholly-owned PD-L1-targeting Probody therapeutic, is being
evaluated in a Phase 1/2 study. CX-072 is part of PROCLAIM (Probody
Clinical Assessment In Man), an international umbrella clinical
trial program that provides clinical trial sites with access to the
Company’s novel therapies under one central protocol. The trial
initiation for CX-2009, a first-in-class Probody drug conjugate
targeting the highly expressed tumor antigen, CD166, is expected
mid-2017. In addition to its proprietary programs, CytomX is
collaborating with strategic partners, including AbbVie,
Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. For more information, visit
www.cytomx.com or follow us on Twitter.
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements. Accordingly, you should
not rely on any of these forward-looking statements, including
those relating to the potential efficacy of CytomX’s product
candidates, the Company’s ability to develop and advance product
candidates into and successfully complete clinical trials,
including the Company’s Phase 1/2 clinical trial of CX-072 and the
timing of any future clinical trials. CX-072 is in the initial
stages of clinical development, we have filed an IND for CX-2009,
and our other product candidates are currently in preclinical
development. The process by which preclinical and clinical
development could potentially lead to an approved product is long
and subject to significant risks and uncertainties. Applicable
risks and uncertainties include those relating to our preclinical
research and development, clinical development, and other risks
identified under the heading "Risk Factors" included in the
Company’s Annual Report on Form 10-Q filed with the SEC on May 5,
2017. The forward-looking statements contained in this press
release are based on information currently available to CytomX and
speak only as of the date on which they are made. CytomX does not
undertake and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Media Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Elizabeth Broader
ebroader@troutgroup.com
646-378-2945
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Sep 2023 to Sep 2024